AbbVie completes acquisition of Cerevel Therapeutics

Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia

Bristol Myers Squibb completes acquisition of Karuna Therapeutics

KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia

Zydus receives USFDA final approval for chlorpromazine hydrochloride injection

Chlorpromazine Hydrochloride Injection is used to treat certain mental/mood disorders

Bristol Myers Squibb to buy Karuna Therapeutics for US$ 14 billion

Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety

Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program

Phase 3 data expected in the second half of 2024

Alembic received 6 USFDA approvals during Q2FY24

The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets

Sumitomo Pharma America launches as new combined organization

SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets

Zydus receives final approval from the USFDA for Olanzapine

Olanzapine Orally Disintegrating Tablets are used to treat certain mental/mood conditions

Alembic receives USFDA tentative approval for Brexpiprazole Tablets

Zydus receives final approval and 180 days shared exclusivity from USFDA for Brexpiprazole tablets

Brexpiprazole is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults